Top 5 bladder cancer articles of 2019
The BCG shortage, overuse of cystoscopy, and hematuria evaluation approaches are among the topics of the most-read Urology Times articles from 2019 on bladder cancer.
Sense of urgency surrounds BCG shortage
As urologists maneuver through the third shortage of bacillus Calmette-Guérin during the past decade, there is a sense of urgency to find short- and long-term alternative treatments to the only FDA-approved BCG strain as a therapeutic agent for nonmuscle-invasive bladder cancer.
Read the article here
Hematuria evaluation: Evidence for optimal practice?
In this blog post, Adele M. Caruso, DNP, CRNP, summarizes current evidence and guidance for hematuria evaluation as it pertains to clinicians, including advanced practice providers.
Read the blog post here
Cystoscopy overuse common in surveillance of low-risk bladder Ca
Despite recommendations for low-intensity cystoscopic surveillance in low-risk non-muscle invasive bladder cancer patients, U.S. Department of Veterans Affairs providers overused cystoscopy in 75% of these patients, according to a study published in Urology (2019; 131:112-9).
Read the article here
Hematuria evaluation approaches compared
“The variability in recommendations [for hematuria evaluation] and our study’s findings highlight implicit value judgments and a potentially high burden of harms not historically considered in many guidelines’ development process," says Matthew E. Nielsen, MD, MS.
Read the article here
Bladder Ca biomarkers and BCG: New knowledge of the urinary microbiome
Study findings have implications for noninvasive markers to predict the course of UCC.
Read the article here
